MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

uniQure NV

Open

56.61 2.93

Overview

Share price change

24h

Current

Min

54.14

Max

57.52

Key metrics

By Trading Economics

Income

5.9M

-38M

Sales

3.7M

5.3M

Profit margin

-716.819

Employees

209

EBITDA

-4.5M

-44M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.36% upside

Dividends

By Dow Jones

Next Earnings

4 lis 2025

Market Stats

By TradingEconomics

Market Cap

2.8B

3.7B

Previous open

53.68

Previous close

56.61

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

uniQure NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 gru 2024, 15:18 UTC

Major Market Movers

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

24 wrz 2025, 18:51 UTC

Earnings

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Peer Comparison

Price change

uniQure NV Forecast

Price Target

By TipRanks

29.36% upside

12 Months Forecast

Average 70.5 USD  29.36%

High 95 USD

Low 55 USD

Based on 12 Wall Street analysts offering 12 month price targets foruniQure NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

10.05 / 14.75Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
help-icon Live chat